CA
NZ
UK
AU
IND
US
…
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing and commercializing abuse-deterrent opioid pain medicines, principally the extended‑release oxycodone product Xtampza ER. Long-term growth may be driven by wider clinical adoption and payer coverage of abuse-deterrent formulations and any portfolio expansion, and investors may find it attractive due to recurring prescription revenue and an established commercial infrastructure.
Material risks include dependence on a single opioid product, competition and pricing pressure from generics and other therapies, and regulatory, reimbursement and litigation exposure related to opioid prescribing; investors should monitor them.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 92.62M | 98.57M | 75.73M | -28.85M | -3.37M |
| Net income | 62.87M | 69.19M | 48.16M | -25.00M | 71.52M |
| Selling general administrative | 284.80M | 172.32M | 151.80M | 172.19M | 118.96M |
| Selling and marketing expenses | - | 10.66M | 7.41M | - | - |
| Gross profit | 463.26M | 377.34M | 326.17M | 209.49M | 150.62M |
| Reconciled depreciation | 226.07M | 169.16M | 149.26M | 138.94M | 68.92M |
| Ebit | 174.93M | 172.54M | 159.07M | -104.57M | -46.70M |
| Ebitda | 401.00M | 341.70M | 308.33M | 34.37M | 22.22M |
| Depreciation and amortization | 226.07M | 169.16M | 149.26M | 138.94M | 68.92M |
| Non operating income net other | - | - | - | 1.05M | 0.01M |
| Operating income | 187.08M | 169.90M | 166.96M | -104.57M | -46.70M |
| Other operating expenses | 593.48M | 461.55M | 399.81M | 430.61M | 254.66M |
| Interest expense | 82.31M | 73.97M | 83.34M | 63.21M | 21.01M |
| Tax provision | 29.75M | 29.38M | 27.58M | -3.85M | -74.89M |
| Interest income | 11.29M | 13.98M | 15.62M | 1.05M | 0.01M |
| Net interest income | -71.02M | -60.00M | -67.72M | -62.17M | -21.00M |
| Non recurring | - | - | - | - | 4.58M |
| Income tax expense | 29.75M | 29.38M | 27.58M | -3.85M | -74.89M |
| Total revenue | 780.57M | 631.45M | 566.77M | 463.93M | 276.87M |
| Total operating expenses | 276.17M | 207.45M | 159.21M | 176.17M | 128.41M |
| Cost of revenue | 317.31M | 254.10M | 240.60M | 254.44M | 126.25M |
| Total other income expense net | -94.47M | -71.33M | -91.23M | 75.73M | 43.33M |
| Net income from continuing ops | 62.87M | 69.19M | 48.16M | -25.00M | 71.52M |
| Net income applicable to common shares | - | - | - | -25.00M | 71.52M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 1656.83M | 1663.59M | 1143.31M | 1174.13M | 692.08M |
| Intangible assets | 669.51M | 891.40M | 421.71M | 567.47M | 268.72M |
| Other current assets | 32.64M | 55.39M | 0.09M | 16.68M | 0.03M |
| Total liab | 1355.16M | 1434.75M | 947.88M | 979.29M | 489.15M |
| Total stockholder equity | 301.68M | 228.84M | 195.43M | 194.84M | 202.93M |
| Other current liab | 398.30M | 424.54M | 264.90M | 66.88M | 147.83M |
| Common stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.04M |
| Capital stock | 0.04M | 0.04M | 0.04M | 0.04M | 0.04M |
| Retained earnings | -101.13M | -164.00M | -233.19M | -281.34M | -256.34M |
| Good will | 145.93M | 162.33M | 133.86M | 133.69M | - |
| Other assets | - | - | - | 19.33M | 942.74M |
| Cash | 251.10M | 70.56M | 238.95M | 173.69M | 186.43M |
| Total current liabilities | 440.03M | 509.51M | 457.92M | 270.11M | 230.40M |
| Current deferred revenue | 0.67M | 10.00M | - | - | - |
| Net debt | 689.46M | 788.73M | 435.34M | 699.10M | 72.32M |
| Short term debt | 30.41M | 65.85M | 184.32M | 163.61M | 49.17M |
| Short long term debt | 29.00M | 64.58M | 183.33M | 162.50M | 48.35M |
| Short long term debt total | 940.56M | 859.30M | 674.28M | 872.79M | 258.75M |
| Other stockholder equity | 402.44M | 392.75M | 428.57M | 476.15M | 459.23M |
| Property plant equipment | - | - | - | 19.52M | 19.49M |
| Total current assets | 691.41M | 482.26M | 537.60M | 419.99M | 315.54M |
| Net tangible assets | - | - | - | -506.32M | -65.80M |
| Short term investments | 155.43M | 92.20M | 71.60M | - | - |
| Net receivables | 211.33M | 228.54M | 179.53M | 183.12M | 105.84M |
| Long term debt | 780.33M | 787.90M | 483.84M | 538.45M | 201.63M |
| Inventory | 40.91M | 35.56M | 32.33M | 46.50M | 17.39M |
| Accounts payable | 10.66M | 3.93M | 8.69M | 39.62M | 33.40M |
| Accumulated other comprehensive income | 0.32M | 0.06M | 0.01M | - | - |
| Common stock total equity | - | - | - | 0.04M | 0.04M |
| Retained earnings total equity | - | - | - | -281.34M | -256.34M |
| Treasury stock | - | - | - | - | -42.86M |
| Non currrent assets other | 20.19M | 9.41M | 0.83M | 2.65M | 2.63M |
| Non current assets total | 965.42M | 1181.33M | 605.71M | 754.14M | 376.53M |
| Capital lease obligations | 5.54M | 6.81M | 7.11M | 8.22M | 8.77M |
| Long term debt total | - | - | - | 538.45M | 201.63M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -61.79M | -287.76M | -46.66M | -573.69M | -1.94M |
| Change to liabilities | - | - | - | -11.84M | -1.05M |
| Total cashflows from investing activities | -63.53M | -287.76M | -70.81M | -573.69M | -1.94M |
| Net borrowings | -70.38M | 7.52M | -65.92M | -75.00M | -50.00M |
| Total cash from financing activities | -110.25M | -60.60M | -140.18M | 436.72M | -89.30M |
| Change to operating activities | - | - | - | -38.50M | 44.13M |
| Net income | 62.87M | 69.19M | 48.16M | -25.00M | 71.52M |
| Change in cash | 155.55M | -143.38M | 63.76M | -12.74M | 12.31M |
| Begin period cash flow | 96.61M | 239.99M | 176.24M | 188.97M | 176.66M |
| End period cash flow | 252.16M | 96.61M | 239.99M | 176.24M | 188.97M |
| Total cash from operating activities | 329.32M | 204.98M | 274.75M | 124.23M | 103.56M |
| Depreciation | 220.82M | 169.16M | 149.26M | 138.94M | 68.92M |
| Other cashflows from investing activities | - | - | - | -572.07M | - |
| Dividends paid | - | - | 9.10M | - | - |
| Change to inventory | -5.35M | 13.93M | 14.17M | 48.27M | -2.30M |
| Change to account receivables | 17.20M | -4.41M | 3.59M | -21.78M | -22.52M |
| Sale purchase of stock | -25.10M | -60.02M | -75.00M | -14.06M | -47.86M |
| Other cashflows from financing activities | -20.40M | -8.10M | 0.74M | 513.98M | 8.56M |
| Change to netincome | - | - | - | 14.48M | -53.79M |
| Capital expenditures | 1.74M | 1.65M | 0.46M | 1.62M | 1.94M |
| Change receivables | - | - | - | -21.78M | -22.52M |
| Cash flows other operating | - | - | - | 109.12M | 39.37M |
| Cash and cash equivalents changes | - | - | - | -12.74M | 12.31M |
| Change in working capital | 3.76M | -54.98M | 21.73M | -12.71M | 13.49M |
| Stock based compensation | 41.91M | 32.40M | 27.14M | 22.87M | 24.25M |
| Other non cash items | 25.62M | 16.02M | 30.62M | 8.52M | 3.42M |
| Free cash flow | 327.58M | 203.33M | 274.29M | 122.61M | 101.61M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| COLL Collegium Pharmaceutical Inc |
-0.21 0.90% |
23.00 | 19.23 | 4.55 | 1.38 | 3.68 | 1.97 | 3.84 |
| MKKGY Merck KGaA ADR |
0.17 0.53% |
32.25 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
- -% |
161.82 | 24.86 | 15.11 | 3.13 | 1.98 | 3.08 | 18.89 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.16 0.78% |
20.27 | - | 10.96 | 0.01 | 1.20 | 2.94 | 23.11 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% |
41.22 | - | 10.66 | 0.01 | 1.16 | 2.94 | 23.11 |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
100 Technology Center Drive, Stoughton, MA, United States, 02072
781 713 3699
423
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael Thomas Heffernan B.S. Pharm, R.Ph. | Co-Founder & Chairman | 1964 |
| Mr. Joseph J. Ciaffoni | Pres, CEO & Director | 1971 |
| Ms. Colleen Tupper | Exec. VP & CFO | 1976 |
| Ms. Shirley R. Kuhlmann | Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec. | 1984 |
| Mr. Scott Dreyer | Exec. VP & Chief Commercial Officer | 1973 |
| Dr. Richard Malamut M.D. | Exec. VP & Chief Medical Officer | 1960 |
| Ms. Alex Dasalla | Head of Investor Relations | NA |
| Mr. Bart J. Dunn | Exec. VP of Strategy & Corp. Devel. | NA |
| Ms. Marlo Manning | Head of HR | NA |
| Mr. Scott Sudduth | Head of Technical Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+1.59%
Communication Services
+0.05%
Consumer Cyclical
+0.14%
Consumer Defensive
-0.43%
Energy
-0.03%
Financial Services
+0.19%
Financials
-0.35%
Healthcare
+1.05%
Industrials
+0.67%
Real Estate
-0.25%
Technology
+1.31%
Utilities
+0.32%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...